anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a sticky gel base and a sticky drug suitable for percutaneous or permucosal treatment by blending a methoxyethylene/maleic acid copolymer, a cross-linked N-vinylacetamide, a polyfunctional epoxy compound, etc. SOLUTION: This gel base consists of a methoxyethylene/maleic acid (anhydride) copolymer (A), a cross-linked N-vinylacetamide (B), a polyfunctional epoxy compound (C), water, and a polyhydric alcohol and is applied to the skin or mucous membrane. It is used to give a sticky drug suitable for the percutaneous or permucosal treatment system and the drug dosage based on the principle of iontophoresis. Preferable amounts of components A, B and C are respectively about 5-35wt.%, about 1-8wt.%, and about 6-180 milli-epoxy- equivalents for 100g of component A. The polyhydric alcohol is blended preferably in an amount of about 10-60wt.%. The component B preferably comprises fine cross-linked polymer particles obtained by cross-linking the main chain of N-vinylacetamide and having an average degree of polymerization of 100 to 500,000.  The component C comprises, e.g. sorbitol polyglycidyl ether.
Participants will continue to receive usual care from their primary care provider, which can include medications, physical therapy, biofeedback, and education according to DoD/VA guidelines for LBP management. Participants randomized to this arm will receive up to five ASP needles per ear placed in the predetermined BFA pattern. Needles are placed until the participant states pain is reduced 1/10.
The invention relates to a method of analyzing an experience of a product or solution. Multiple input features are defined for a type of participant. An input feature is a measurable quantity of an interaction with the product or solution, and is related to an experience driver that affects experience. Multiple training records are collected, comprising values of the multiple input features and an overall experience score. Based on the multiple training records, a machine learning model is trained to infer the experience score from at least the multiple input features. Importance weights of the input features are derived indicating an importance assigned by the machine learning model to the input feature, and output e.g. to a user as feedback about a relative importance of the respective input features on the experience.
PROBLEM TO BE SOLVED: To obtain a low-irritant cleansing agent excellent in both removing and cleansing effect on makeup cosmetics, and easily washable off with water after cleansing. SOLUTION: This anhydrous transparent liquid cleansing agent contains a soap consisting of pref. 20-50wt.% of a salt of 10-22C fatty acid mixture (pref. salt of at least two kinds of fatty acid and at least one kind of basic aliphatic amine) and pref. 30-60wt.% of a polyhydric alcohol. This cleansing agent excellent in transparency, good in usability, also good in compatibility with makeup cosmetics, and can be washed off with water after cleansing.
Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Participants receive anti-thymocyte globulin IV over 4-6 hours on days -3 to -1. Beginning day -1, participants also receive tacrolimus IV or cyclosporine IV BID tapered at day 50, and methotrexate IV on days 1, 3, 6 and 11 in the absence of disease progression or unacceptable toxicity.
A nucleic acid enzyme with allosteric RNA-cleaving activity on a target RNA. An expression vector containing a DNA coding for the nucleic acid enzyme. A method for producing the nucleic acid enzyme, in which an expression vector DNA containing a DNA encoding the nucleic acid enzyme is used as a template in the transcription to RNA. A pharmaceutical composition containing the nucleic acid enzyme or the expression vector containing the DNA coding for the nucleic acid enzyme as an effective component. A method for specifically cleaving target RNA by using the nucleic acid enzyme.  <IMAGE>
OBJECTIVE: This study aimed to identify significantly differentially expressed genes (DEGs) related to cervical cancer by exploring extensive gene expression datasets to unveil new therapeutic targets.
METHODS: Gene expression profiles were extracted from the Gene Expression Omnibus, The Cancer Genome Atlas, and the Genotype-Tissue Expression platforms. A differential expression analysis identified DEGs in cervical cancer cases. Weighted gene co-expression network analysis (WGCNA) was implemented to locate genes closely linked to the clinical traits of diseases. Machine learning algorithms, including LASSO regression and the random forest algorithm, were applied to pinpoint key genes.
RESULTS: The investigation successfully isolated DEGs pertinent to cervical cancer. Interleukin-24 was recognized as a pivotal gene via WGCNA and machine learning techniques. Experimental validations demonstrated that human interleukin (hIL)-24 inhibited proliferation, migration, and invasion, while promoting apoptosis, in SiHa and HeLa cervical cancer cells, affirming its role as a therapeutic target.
CONCLUSION: The multi-database analysis strategy employed herein emphasized hIL-24 as a principal gene in cervical cancer pathogenesis. The findings suggest hIL-24 as a promising candidate for targeted therapy, offering a potential avenue for innovative treatment modalities. This study enhances the understanding of molecular mechanisms of cervical cancer and aids in the pursuit of novel oncological therapies.
Scalp psoriasis can be treated with a novel fiber optic delivery system that irradiates the psoriatic scalp of patients with UV-B light via an optical fiber comb. Current methods for treatment of psoriasis with light are not applicable to the scalp because hair is usually blocking the light from reaching the affected skin. Our method overcomes this problem with the use of a comb that has optical fibers to deliver light directly to the skin. We have developed a UV-B light source and a fiber optic comb for use in clinics and doctors' offices. We will evaluate this device in a clinical setting.

The results of this trial will provide data about the effectiveness of the device. We will use these results to tailor the design before it is ready for volume production. If successful, the UV-B light source and fiber optic comb will provide treatment to people affected with scalp psoriasis. At present, these people do not have any effective treatment available to them.
Patients receive nab-paclitaxel IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine IV over 30 minutes on days 1 and 15 of each cycle. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease, partial or complete response undergo surgical resection per standard of care. Additionally, patients undergo biopsy on study and undergo blood sample collection and CT or MRI at pre-study and on study.
Both control and experimental cohorts will be recruited in this study. In order to drive clinical acceptance of this technique, the investigators will need to study and then demonstrate applicability to all patients regardless of race or gender. This will require the recruitment of a control population of patients who have been demonstrated at surgery to be easy to intubate. Such patients are in relative abundance. The experimental group will consist of patients who are found at surgery to be difficult to intubate. In addition, a prospective cohort will be recruited without prior knowledge of ease or difficulty of intubation, and subsequent ground truth determined at surgery. Patients are defined as easy to intubate if their anesthetic record described a single attempt with a Macintosh 3 blade resulting in a grade 1 laryngoscopic view (full exposure of the vocal cords). Difficult intubation was defined by at least one of: more than one attempt by an operator with at least one year of anesthesia experience, grade 3 or 4 laryngoscopic view on a 4 point scale, 5 need for a second operator, or non-elective use of an alternative airway device such as a bougie, fiberoptic bronchoscope or intubating laryngeal mask airway.

The primary purpose of the study is to develop algorithms capable of discriminating patients who are likely to be difficult to intubate from those who are likely to be easy to intubate based on facial appearance. The primary analysis is the demonstration of statistical significance in the ability of the derived algorithms to determine successfully whether a subject was easy or difficult to intubate. A secondary analysis is the demonstration of a statistical difference in performance between the derived algorithms versus conventional airway assessment tests.

An ongoing modification of the protocol will allow anesthesia personnel to attempt intubation with a Miller (straight) laryngoscope blade, instead of a Macintosh blade. This secondary outcome was chosen because of the strong preference, and in some cases, better skill, with such a blade. It is possible that different facial features will predict difficulty with this blade than has been predicted to date with a Macintosh blade.
Distinct neutrophil populations arise during certain pathological conditions. The generation of dysfunctional neutrophils during sepsis and their contribution to septicemia-related systemic immune suppression remain unclear. In this study, using an experimental sepsis model that features immunosuppression, we identified a novel population of pathogenic CD200Rhigh neutrophils that are generated during the initial stages of sepsis and contribute to systemic immune suppression by enhancing regulatory T (Treg) cells. Compared to their CD200Rlow counterparts, sepsis-generated CD200Rhigh neutrophils exhibit impaired autophagy and dysfunction, with reduced chemotactic migration, superoxide anion production, and TNF-α production. Increased soluble CD200 blocks autophagy and neutrophil maturation in the bone marrow during experimental sepsis, and recombinant CD200 treatment in vitro can induce neutrophil dysfunction similar to that observed in CD200Rhigh neutrophils. The administration of an α-CD200R antibody effectively reversed neutrophil dysfunction by enhancing autophagy and protecting against a secondary infection challenge, leading to increased survival. Transcriptome analysis revealed that CD200Rhigh neutrophils expressed high levels of Igf1, which elicits the generation of Treg cells, while the administration of an α-CD200R antibody inhibited Treg cell generation in a secondary infection model. Taken together, our findings revealed a novel CD200Rhigh neutrophil population that mediates the pathogenesis of sepsis-induced systemic immunosuppression by generating Treg cells.
PROBLEM TO BE SOLVED: To easily prepare individual concrete data by synthesizing main and subordinate data separately displayed on both sides of the screen of a computer at the center of the screen. SOLUTION: A customer ledger 431 and a commodity ledger 432 are prepared as data bases. Customer data are retrieved from the customer ledger 431 based on a customer retrieving condition and the retrieved customer data are displayed on one side of a screen 100. Commodity retrieval information which becomes a candidate is prepared by referring to the customer data displayed on the right side of the screen 100 and the commodity to be related to a customer is retrieved from the commodity ledger 432 based on the commodity retrieval condition and displayed on the other side of the screen 100. The customer information displayed on one side of the screen 100 is moved to the center of the screen 100 and the commodity displayed on the other side of the screen 100 is also moved to the center of the screen 100 and displayed in detail.  Then the customer data and the detail of the commodity data are synthesized and displayed at the center of the screen 100. The synthesized and displayed data are outputted as data.
Hemophagocytic lymphohistiocytosis (HLH) has occurred in pediatric and adult patients taking lamotrigine for various indications. HLH is a life-threatening syndrome of pathologic immune activation characterized by clinical signs and symptoms of extreme systemic inflammation. It is associated with high mortality rates if not recognized early and treated. Common findings include fever, hepatosplenomegaly, rash, lymphadenopathy, neurologic symptoms, cytopenias, high serum ferritin, hypertriglyceridemia and liver function and coagulation abnormalities. In cases of HLH reported with lamotrigine, patients have presented with signs of systemic inflammation (fever, rash, hepatosplenomegaly, and organ system dysfunction) and blood dyscrasias. Symptoms have been reported to occur within 8 to 24 days following the initiation of treatment. Patients who develop early manifestations of pathologic immune activation should be evaluated immediately, and a diagnosis of HLH should be considered. lamotrigine should be discontinued if an alternative etiology for the signs or symptoms cannot be established.
The intratumoral microbiota can modulate the tumor immune microenvironment (TIME); however, the underlying mechanism by which intratumoral microbiota influences the TIME in urothelial carcinoma of the bladder (UCB) remains unclear. To address this, we collected samples from 402 patients with UCB, including paired host transcriptome and tumor microbiome data, from The Cancer Genome Atlas (TCGA). We found that the intratumoral microbiome profiles were significantly correlated with the expression pattern of epithelial-mesenchymal transition (EMT)-related genes. Furthermore, we detected that the genera Lachnoclostridium and Sutterella in tumors could indirectly promote the EMT program by inducing an inflammatory response. Moreover, the inflammatory response induced by these two intratumoral bacteria further enhanced intratumoral immune infiltration, affecting patient survival and response to immunotherapy. In addition, an independent immunotherapy cohort of 348 patients with bladder cancer was used to validate our results. Collectively, our study elucidates the potential mechanism by which the intratumoral microbiota influences the TIME of UCB and provides a new guiding strategy for the targeted therapy of UCB.NEW & NOTEWORTHY The intratumoral microbiota may mediate the bladder tumor inflammatory response, thereby promoting the epithelial-mesenchymal transition program and influencing tumor immune infiltration.
This is a prospective, randomized, open label, parallel, 16-week study to explore and evaluate the therapeutic effects of liraglutid, dapagliflozin and acarbose on the cognitive function, olfactory function, and odor-induced brain activation in overweight/obese patients with T2DM inadequately controlled with metformin monotherapy.We have 1 principle investigator, 6 sub-investigators and 1 nurse in research centre. The sub-investigators will screen in the outpatient and inpatient departments to enroll 87 patients (29 for each arm) totally with the inclusion and exclusion criteria in 12 months. The patients will be randomized at a 1:1:1 ratio into liraglutid, dapagliflozin and acarbose treatment group with a computer-generated random order. All patients will also continue on their existing dose and regimen of metformin throughout the study. At the baseline, clinical information collection, 100g-steamed bread meal test, biochemical measurement, body composition analysis, cognitive assessment, olfactory test and functional magnetic resonance imaging(fMRI) scan will be conducted for all patients. During the treatment period, visits at 4-week intervals will be performed to evaluate the safety of drugs and adjust the dose of metformin if hypoglycaemia occurs; meanwhile, fasting and 2-hour postprandial plasma glucose assayed by fingerstick, physical examination, and olfactory test will be conducted. At the end of the study, all of the assessments will be performed again for all recruited subjects, including early withdrawal patients.
Alcohol use disorder (AUD) is a common and difficult disorder to treat. Only a fraction of sufferers seek treatment and the rate of relapse is high. There is therefore an urgent need for improved methods of promoting long term abstinence and recovery in AUD. This study will explore the effectiveness of a smartphone application, UControlDrink, in aiding recovery from AUD in patients who have been discharged from an inpatient alcohol treatment programme. The application comprises five recovery focused features:

supportive messages, Computerised-Cognitive Behavioural Therapy, a drinking log, activities and trigger avoidance log, craving management and gamification. Patients will use the application for 3 months. A control group of patients will also be followed over the same time period. Cumulative abstinence duration as well as changes in questionnaire measures to baseline, time to first drink, proportion of patients continuously abstinent from alcohol, levels of activity within the app and patient satisfaction with their overall treatment will be measured at 3 months. If successful, this application may offer a unique, patient-centred, technology-driven, cost effective method of improving outcomes in AUD.
Pirfenidone belongs to the chemical class of pyridone. Pirfenidone capsules are available as white hard gelatin capsules containing 267 mg of pirfenidone for oral administration.

Pirfenidone has a molecular formula of C12H11NO and a molecular weight of 185.23. Pirfenidone has the following structural formula, which has been referred to as 5-methyl-1-phenyl-2-1(H)-pyridone or 5-methyl-1-phenyl-2-(1H)-pyridone.

Pirfenidone is a white to pale yellow crystalline, non-hygroscopic powder. It is more soluble in methanol, ethyl alcohol, acetone and chloroform than in water and 1.0 N HCl. The melting point is approximately 108°C.

Pirfenidone capsule contains pirfenidone and the following inactive ingredients: croscarmellose sodium, hypromellose, magnesium stearate, and pregelatinized starch. 

In addition, the capsule shell contains gelatin and titanium dioxide. The capsule black printing ink includes iron oxide black, potassium hydroxide, propylene glycol, shellac and strong ammonia solution.
OBJECTIVE: The objective of the meta-analysis was to determine the influence of uterine fibroids on adverse outcomes, with specific emphasis on multiple or large (≥ 5 cm in diameter) fibroids.
MATERIALS AND METHODS: We searched PubMed, Embase, Web of Science, ClinicalTrials.gov, China National Knowledge Infrastructure (CNKI), and SinoMed databases for eligible studies that investigated the influence of uterine fibroids on adverse outcomes in pregnancy. The pooled risk ratio (RR) of the variables was estimated with fixed effect or random effect models.
RESULTS: Twenty-four studies with 237 509 participants were included. The pooled results showed that fibroids elevated the risk of adverse outcomes, including preterm birth, cesarean delivery, placenta previa, miscarriage, preterm premature rupture of membranes (PPROM), placental abruption, postpartum hemorrhage (PPH), fetal distress, malposition, intrauterine fetal death, low birth weight, breech presentation, and preeclampsia. However, after adjusting for the potential factors, negative effects were only seen for preterm birth, cesarean delivery, placenta previa, placental abruption, PPH, intrauterine fetal death, breech presentation, and preeclampsia. Subgroup analysis showed an association between larger fibroids and significantly elevated risks of breech presentation, PPH, and placenta previa in comparison with small fibroids. Multiple fibroids did not increase the risk of breech presentation, placental abruption, cesarean delivery, PPH, placenta previa, PPROM, preterm birth, and intrauterine growth restriction. Meta-regression analyses indicated that maternal age only affected the relationship between uterine fibroids and preterm birth, and BMI influenced the relationship between uterine fibroids and intrauterine fetal death. Other potential confounding factors had no impact on malposition, fetal distress, PPROM, miscarriage, placenta previa, placental abruption, and PPH.
CONCLUSION: The presence of uterine fibroids poses increased risks of adverse pregnancy and obstetric outcomes. Fibroid size influenced the risk of breech presentation, PPH, and placenta previa, while fibroid numbers had no impact on the risk of these outcomes.
Infants in Cohort 1 received a single VRC01LS injection less than 72 hours after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater.
Continuous infusions of remifentanil HCl should be administered only by an infusion device. IV bolus administration of remifentanil HCl should be used only during the maintenance of general anesthesia. In nonintubated patients, single doses of remifentanil HCl should be administered over 30 to 60 seconds. 

Interruption of an infusion of remifentanil HCl will result in rapid offset of effect. Rapid clearance and lack of drug accumulation result in rapid dissipation of respiratory depressant and analgesic effects upon discontinuation of remifentanil HCl at recommended doses. Discontinuation of an infusion of remifentanil HCl should be preceded by the establishment of adequate postoperative analgesia.

Injections of remifentanil HCl should be made into IV tubing at or close to the venous cannula. Upon discontinuation of remifentanil HCl, the IV tubing should be cleared to prevent the inadvertent administration of remifentanil HCl at a later point in time. Failure to adequately clear the IV tubing to remove residual remifentanil HCl has been associated with the appearance of respiratory depression, apnea, and muscle rigidity upon the administration of additional fluids or medications through the same IV tubing.
Subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Second treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Third treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR.
PURPOSE: A pharmaceutical composition and health functional food containing a Hedera rhombea extract for preventing and treating diabetes complication are provided to suppress aldose reductase activity, and to prevent or treat diabetic ophthalmic diseases. CONSTITUTION: A pharmaceutical composition for preventing or treating diabetes complication contains a Hedera rhombea extract or a fraction thereof as an active ingredient. The extract is prepared from branches, leaves, or roots of Hedera rhombea using water, methanol, ethanol, ethyl acetate, or a mixture thereof. The extract is prepared by room temperature extraction, hot water extraction, enfleurage, reflux extraction, sonication, or steaming. The fraction is prepared by suspending the ethanol extract of Hedera rhombea in water, and fractioning with ethyl acetate. Health functional food for preventing or treating diabetes complication contains the extract or the fraction as an active ingredient. [Reference numerals] (AA) Hedera rhombea extract(HR); (BB) Ethyl acetate, water; (CC) Ethyl acetate fraction(E); (DD) Water layer; (EE) Butanol; (FF) Butanol fraction(B); (GG) Water fraction(W)